Loading...
•
Dec 31, 2023
Innoviva Q4 2023 Earnings Report
Innoviva reported Q4 2023 financial results, highlighting company progress with its core royalty platform and advancements in its therapeutics platform.
Key Takeaways
Innoviva reported strong cash flow from its core royalty portfolio and significant pipeline and commercial progress in its therapeutics platform. The company ended the year with over $275 million in cash and account receivables, while returning capital with share repurchases of over $75 million and paying down outstanding debt of nearly $100 million.
Received GSK royalties of $69.6 million for the fourth quarter.
Achieved net product revenues of $19.7 million for the fourth quarter of 2023, representing 35% year-on-year growth.
Approval and launch of first pathogen targeted antibacterial XACDURO® for treatment of HABP/VABP caused by Acinetobacter infections.
Repurchased 1.1 million of common stock for $15.4 million in the fourth quarter of 2023.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Innoviva's diversified growth strategy, strong leadership team, and focus on cost discipline position it well to deliver shareholder value.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...